: Is this related to a specific production code for a video or creative project? Internal Filing
The origins of the JUQ-470 date back to [insert time frame], when researchers and engineers embarked on a mission to create a cutting-edge solution that would address specific needs and challenges. Through rigorous testing, experimentation, and refinement, the JUQ-470 began to take shape, incorporating the latest advancements in [relevant field]. JUQ-470
| Target | Type of inhibition | Reported IC₅₀ (nM) | Relevance in cancer | |--------|-------------------|-------------------|---------------------| | | ATP‑competitive | 12 ± 3 | Drives proliferation in breast, lung, and bladder cancers with FGFR1 amplification. | | VEGFR2 (vascular endothelial growth factor receptor 2) | ATP‑competitive | 18 ± 2 | Critical for angiogenesis; inhibition reduces tumor vascular supply. | | Additional off‑targets | Low‑nanomolar binding to PDGFRβ and c‑KIT (reported in broad kinase panels) | 45–90 | May contribute to broader antitumor activity but raise potential safety signals. | : Is this related to a specific production
| Model | Dose (mg/kg) | Schedule | Tumor growth inhibition (TGI) | Key observations | |-------|--------------|----------|------------------------------|-------------------| | | 30 | q.d. (once daily) oral | 85 % | Significant tumor shrinkage; complete regressions in 2/6 mice. | | VEGF‑overexpressing colon carcinoma (HT‑29 xenograft) | 25 | q.d. oral | 78 % | Reduced microvessel density (CD31 IHC) by 65 %. | | Patient‑derived xenograft (PDX) from FGFR1‑amplified breast cancer | 40 | q.d. oral | 92 % | Durable response, delayed tumor re‑growth for >30 days post‑treatment. | | Safety/toxicity (rat 28‑day repeat dose) | 10‑100 mg/kg | q.d. oral | No lethal toxicity; observed reversible elevation of ALT/AST at ≥50 mg/kg. | No significant weight loss; mild gastrointestinal irritation noted. | | Target | Type of inhibition | Reported
If you provide more details about what "JUQ-470" refers to, I could offer a more specific and tailored draft.